APPLICATION
Etoricoxib is a non-steroidal anti-inflammatory drug, which has anti-inflammatory, analgesic and antipyretic effects in animal models. It is a selective cyclooxygenase-2 inhibitor with oral activity within the clinical dose range or higher. Two subtypes of cyclooxygenase have been identified: cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). COX-1 participates in the normal physiological functions mediated by prostaglandin, such as gastric mucosal cell protection and platelet aggregation. Non-selective non-steroidal anti-inflammatory drugs inhibit the production of COX-1, which can cause gastric mucosal damage and weaken platelet aggregation. COX-2 is mainly involved in the production of prostaglandins, and prostaglandins can cause pain, inflammation and fever. Etoricoxib is a selective cyclooxygenase-2 inhibitor, which can alleviate these symptoms and signs, reduce gastrointestinal side effects without affecting platelet function.